Why are there no proven therapies for genetic mitochondrial diseases?

Mitochondrion

Volumn 11, Issue 5, 2011, Pages 679-685

  Stacpoole, Peter W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Clinical trials; Coenzyme Q10; Dichloroacetate; Mitochondria; Mitochondrial diseases

Indexed keywords

ASCORBIC ACID; DICHLOROACETIC ACID; MENADIONE; PLACEBO; UBIDECARENONE;

CLINICAL TRIAL (TOPIC); DISORDERS OF MITOCHONDRIAL FUNCTIONS; FUNDING; HEALTH CARE COST; HUMAN; LACTIC ACIDOSIS; MEDICAL RESEARCH; MELAS SYNDROME; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SHORT SURVEY;

ACIDOSIS, LACTIC; ANIMALS; DICHLOROACETATE; FINANCING, GOVERNMENT; HUMANS; MELAS SYNDROME; MITOCHONDRIAL DISEASES; NEGLECTED DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; SOCIETIES, MEDICAL; UBIQUINONE; UNITED STATES;

EID: 79961209538     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2011.05.002     Document Type: Short Survey

References (48)

1. Anderson S., Bankier A.T., Barrel B.G., De Bruijn M.H.L., Coulson A.R., Drouin J., Eperon I.C., Nierlich D.P., Roe B.A., Sanger F., Schreier P.H., Smith A.J., Staden R., Young I.G. Sequence and organization of the human mitochondrial genome. Nature 1981, 290:457-465.
2. Arogov Z., Bank W.J., Maris J., Eleff S., Kennaway N.G., Olson R.E., Chance B. Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: a 31P-NMR follow-up study. Ann. Neurol. 1986, 19:598.
3. Balaban R.S., Nemoto S., Finkel T. Mitochondrial, oxidants and aging. Cell 2005, 120:483-495.
4. Barshop B.A., Naviaux R.K., McGowan K.A., Levine F., Nyhan W.L., Loupis-Geller A., Haas R.H. Chronic treatment of mitochondrial disease patients with dichloroacetate. Mol. Genet. Metab. 2004, 83(1-2):138-149.
5. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann NY Acad Sci 2003, 991:120-131.
6. Berendzen K., Theriaque D., Shuster J., Stacpoole P.W. Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency. Mitochondrion 2006, 6:126-135.
7. Calcutt N.A., Lopez V., Batusta A., Mizisin L., Cunha J.M., Shroads A.L., Mizisin A.P., Stacpoole P.W. Peripheral neuropathy in rats exposed to dichloroacetate. J Neuro Sci Exp Neurol 2009, 68:985-993.
8. Chinnery P.F., Samuels D.C., Elson J., Turnbull D.M. Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism?. Lancet 2002, 360(9342):1323-1325.
9. Coude F.X., Saudbray J.M., DeMaugre F., Marsac C., Leroux J.P., Charpentier C. Dichloroacetate as treatment for congenital lactic acidosis. N. Engl. J. Med. 1978, 299(24):1365-1366.
10. DiMauro S., Hirano M., Schon E.A. Mitochondrial Medicine 2006, Informa Healthcare, Oxon, United Kingdom.
11. Duncan G.E., Perkins L.A., Theriaque D.W., Neiberger R.E., Stacpoole P.W. Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism. J. Clin. Endocrinol. Metab. 2004, 89(4):1733-1738.
12. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460(7255):587-591.
13. Geromel V., Darin N., Chretien D., Bénit P., DeLonlay P., Rötig A., Munnich A., Rustin P. Coenzyme Q10 and idebenone in the therapy of respiratory chain disorders: rationale and comparative benefits. Molecular Genetics and Metabolism 2002, 77:21-30.
14. Glover E.I., Martin J., Maher A., Thornhill R.E., Moran G.R., Tarnopolsky M.A. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010, 42(5):739-748.
15. Gvozdjakova A. Mitochondrial Medicine: Mitochondrial Metabolism, Diseases, Diagnosis and Therapy 2008, Springer Science.
16. Haas R.H. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion 2007, 7S:S136-S145.
17. Holt I.J., Harding A.E., Morgan Huges J.A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988, 321:717-719.
18. Kaufmann P., Engelstad K., Wei Y., Jhung S., Sano M.C., Shungu D.C., Millar W.S., Hong X., Gooch C.L., Mao X., Pascual J.M., Hirano M., Stacpoole P.W., DiMauro S., Di Vivo D.C. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006, 66:324-330.
19. Kaufmann P., Thompson J.L.P., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., Katz J., Rollins Y., Barohn R.J., Jackson C.E., Tiryaki E., Lomen-Hoerth C., Armon C., Tandan R., Rudnicki S.A., Rezania K., Sufit R., Pestronk A., Novella S.P., Heiman-Patterson T., Kasarskis E.J., Pioro E.P., Montes J., Arbing R., Vecchio D., Barsdorf A., Mitsumoto H., Levin B. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009, 66:235-244.
20. Kerr D.S. Treatment of lactic acidosis: a review. Int Pediatr 1995, 10:75-81.
21. Klopstock T., Querner V., Schmidt F., Gekeler F., Walter M., Hartard M., Henning M., Gasser T., Pongratz D., Straube A., Dieterich M., Müller-Felber W. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000, 55(11):1748-1751.
22. Kornblum C., Schröder R., Müller K., Vorgerd M., Eggers J., Bogdanow M., Papassotiropoulos A., Fabian K., Klockgether T., Zange J. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. Eur. J. Neurol. 2005, 12(4):300-309.
23. Phase 3 trial of coenzyme. Q10 in genetic mitochondrial diseases 2008, Kurtz, TL, for the CoQ10 Trial Investigators, United Mitochondrial Disease Foundation, Indianapolis, IN, June 24-28.
24. Lamperti C., Naini A., Hirano M., De Vivo D.C., Bertini E., Servidei S., Valeriani M., Lynch D., Banwell B., Berg M., Dubrovsky T., Chiriboga C., Angelini C., Pegoraro E., DiMauro S. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 2003, 60:1206-1208.
25. Lenaz G., Baracca A., Fato R., Genova M.L., Solaini G. New insights into structure and function of mitochondria and their role in aging and disease. Antioxid. Redox Signal. 2006, 8(3-4):417-437.
26. Liet J.M., Pelletier V., Robinson B.H., Laryea M.D., Wendel U., Morneau S., Morin C., Mitchell G., Lacroix J. The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. J. Pediatr. 2003, 142(1):62-66.
27. Mancuso M., Orsucci D., Volpi L., Calsolaro V., Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr. Drug Targets 2010, 11(1):111-121.
28. Matthews P.M., Ford B., Dandurand R.J., Eidelman D.H., O'Connor D., Sherwin A., Karpati G., Andermann F., Arnold D.L. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993, 43:884-890.
29. Musumeci O., Naini A., Slonim A.E., Skavin N., Hadjigeorgiou G.L., Krawiecki N., Weissman B.M., Tsao C.Y., Mendell J.R., Shanske S., De Vivo D.C., Hirano M., DiMauro S. Familial cerebellar ataxia with muscle Q10 deficiency. Neurology 2001, 56:849-855.
30. Ogasahara S., Engel A.G., Frens D., Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalopathy. Proc Natl Acad Sci USA 1989, 86:2379-2382.
31. Peterson P.L. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim. Biophys. Acta 1995, 1271:275-280.
32. Rhodes S. Images of America: Angel Flight Mid-Atlantic 2008, Arcadia Publishing.
33. Rodriguez M.C., MacDonald J.R., Mahoney D.J., Parise G., Beal M.F., Tarnopolsky M.A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Nuscle Nerve 2007, 35(2):235-242.
34. Rodriguez M.C., MacDonald J.R., Mahoney D.J., Parise G., Beal M.F., Tarnopolsky M.A. Beneficial effects of creatine, CoQ10 and lipoic acid in mitochondrial disorders. Muscle Nerve 2007, 35:235-242.
35. Sackett D.L. Rules of evidence and clinical recommendations for the management of patients. Can. J. Cardiol. 1993, 9:487-489.
36. Shroads A.L., Guo X., Dixit V., Liu H.-P., James M.O., Stacpoole P.W. Age-dependent metabolism of dichloroacetate in rats: possible relevance to human toxicity. J Pharmacol Exper Ther 2008, 324:1163-1171.
37. Stacpoole P.W. The dichloroacetate dilemma: environmental hazard vs. therapeutic goldmine - both or neither?. Environ. Health Perspect. 2011, 119(2):155-158.
38. Stacpoole P.W., Gilbert L.R., Neiberger R.E., Carney P.R., Valenstein E., Theriaque D.W., Shuster J.J. Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics 2008, 121:e1223-e1228.
39. Stacpoole P.W., Kerr D.S., Barnes C., Bunch S.T., Carney P.R., Fennell E.M., Felitsyn.N.M, Gilmore R.L., Greer M., Henderson G.N., Hutson A.D., Neiberger R.E., O'Brien R.G., Perkins L.A., Quisling R.G., Shroads A.L., Shuster J.J., Silverstein J.H., Theriaque D.W., Valenstein E. A controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006, 117:1519-1531.
40. Stacpoole P.W., Henderson G.N., Yan Z., Cornett R., James M.O. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab. Rev. 1998, 30:499-539.
41. Stacpoole P.W., Barnes C.L., Hurbanis M.D., Cannon S.L., Kerr D.S. Treatment of congenital lactic acidosis with dichloroacetate. Arch. Dis. Child. 1997, 77:535-541.
42. Stacpoole P.W. The pharmacology of dichloroacetate. Metabolism 1989, 38:1124-1144.
43. Stamelou M., Reuss A., Pilatus U., Magerkurth J., Niklowitz P., Eggert K.M., Krisp A., Menke T., Schade-Brittinger C., Oertel W.H., Höglinger G.U. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Movement Disorders 2008, 23(7):942-949.
44. Tarnopolsky M.A., Roy B.D., MacDonald J.R. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997, 20(12):1502-1509.
45. The Huntington Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404.
46. The Huntington Study Group Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov. Disord. 2010, 25(12):1924-1928.
47. Turunen M., Olsson Dallner G. Metabolism and function of coenzyme Q. Biochim. Biophys. Acta 2004, 1660:171-199.
48. Wallace D.C., Singh G., Lott M.T., Hodge J.A., Schurr T.G., Lezza A.M., Elsas L.J., Nikoskelainen E.K. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988, 242:1427-1430.